Ligand-targeted therapeutics in anticancer therapy
Top Cited Papers
- 1 October 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 2 (10) , 750-763
- https://doi.org/10.1038/nrc903
Abstract
Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can selectivity be improved? One strategy is to couple the therapeutics to antibodies or other ligands that recognize tumour-associated antigens. This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted therapeutics.Keywords
This publication has 84 references indexed in Scilit:
- Engineered antibodies take center stageHuman Antibodies, 2001
- Improving the efficacy of antibody-based cancer therapiesNature Reviews Cancer, 2001
- Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-tag-72 single-chain FvsInternational Journal of Cancer, 2001
- Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugatesAdvanced Drug Delivery Reviews, 2001
- Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal TrialsOncology, 2001
- Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent DevelopmentsCancer Investigation, 2001
- Antibody EngineeringAnnual Review of Biomedical Engineering, 2000
- Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor SubfamilyDrugs, 2000
- Liposome targeting to tumors using vitamin and growth factor receptorsPublished by Elsevier ,2000
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975